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Abstract 
Aim To estimate the effectiveness of colorectal cancer screening with faecal occult 
blood testing (FOBT), flexible sigmoidoscopy (FS), and combinations of FOBT and 
FS in preventing colorectal cancer (CRC) deaths. 
Method A systematic review was conducted examining randomised controlled trials 
(RCTs) published between 1997 and 2004 inclusive. A systematic search of Medline, 
Embase, Current Contents, and the Cochrane Library was undertaken. Studies that 
evaluated screening with FOBT, FS or combinations of FOBT and FS, were 
appraised. A meta-analysis of population-based trials of FOBT was conducted. 
Results Four RCTs were identified that examined FOBT screening. The three trials 
that investigated guaiac-based FOBT found CRC mortality was reduced in the 
screening group. In the two population-based trials, the pooled relative risk was 0.86 
(95%CI 0.79–0.93). A fourth RCT was identified, with shorter term follow-up, which 
considered FOBT screening combined with FS compared with FOBT alone. No 
significant reduction in CRC mortality was reported in this trial.  
Conclusion There is high-quality evidence showing that guaiac-based FOBT 
screening reduces mortality from CRC. No such evidence exists for screening with FS 
either alone, or in combination with FOBT, but this should be re-evaluated once data 
become available from four large ongoing trials.  
At present, there is no routine organised population screening for colorectal cancer 
(CRC) in New Zealand. Concerns about high rates of mortality1 and morbidity2 from 
CRC in New Zealand have led to calls for population screening for the disease.  
Proposed methods include faecal occult blood testing (FOBT), flexible 
sigmoidoscopy (FS), and combinations of these. In order to update a literature review 
completed in New Zealand in 1998,3,4 a systematic review was conducted of the 
evidence for the clinical effectiveness of population screening for CRC using FOBT, 
FS, and FOBT and FS combined.5 This paper focuses on CRC mortality and 
incidence. Colonoscopy, double contrast barium enema, and computed tomographic 
(CT) colonoscopy have also been suggested as possible screening tests but were not 
considered in this review due to the absence of new randomised controlled trial (RCT) 
efficacy data since 1998.  
Methods 
Search strategy—A systematic search of Medline, Embase, Current Contents, and the Cochrane 
Library was conducted. Extended searching included the DARE and Health Technology Assessment 
databases, clinical trial and guideline resources, and references from retrieved publications. Searches 
were limited to material published from January 1997 to November 2004 inclusive.  
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Study selection—Studies were eligible for inclusion in the review if they were full reports of RCTs 
that compared the clinical effectiveness of FOBT screening with no screening. Studies evaluating other 
screening methods including FS, and combined FS and FOBT approaches, were also considered. When 
there was more than one version of the study, the version with the longer follow-up was used.  
Data extraction and synthesis—Data relevant to study quality and statistical precision were extracted 
using design-relevant checklists.6 Key data extracted included characteristics of the study population, 
intervention and control group, sample size (by study group), number of screening rounds, duration of 
follow-up, and management of patients who were screen positive.  
Results data for CRC incidence and mortality risk ratios, and positive predictive values, were either 
obtained directly from the studies or derived from available information. An analysis of numbers 
needed to screen (NNS) to prevent one CRC death was based on an intention to screen basis, using the 
groups that subjects were originally randomised to, although the limitations of this measure are 
recognised.7 Confidence intervals for the NNS were calculated using the method suggested by Altman 
for number needed to test.8 
The most recently published data, examining the effectiveness of screening with FOBT in reducing 
CRC mortality from the population-based RCTs, were used to conduct a meta-analysis. As there was 
no suggestion of heterogeneity, a fixed effects model meta-analysis was undertaken, using Stata 
(version 7.0) software.9 
Full details of search terms, sources, study selection, and appraisal methods are provided in the 
NZHTA report.5 
Results 
Efficacy of faecal occult blood screening—The current review identified four RCTs 
comparing FOBT screening with no screening. Three of these trials used the guaiac 
test Haemoccult/Haemoccult II. The other trial used an immunochemical test (reverse 
passive haemaggutination) plus a health questionnaire.16 Study design details are 
included in Table 1. 
After 18 years follow-up in the Minnesota RCT, CRC mortality was significantly 
reduced in the annual group (21% reduction) and the biennial group (17% reduction). 
CRC incidence in the annual and biennial screening groups was also significantly 
reduced in this trial, by 33% and 21% respectively (see Table 2).10,11 After a median 
of 11.7 years follow-up in the Nottingham trial, a 13% reduction in CRC mortality 
was reported for those in the screening group compared to the control group.12 
However, there was no significant difference in CRC incidence between the screening 
and control groups (see Table 2).  
After 17 years of screening (nine screening rounds) in the Funen-1 trial, CRC 
mortality was reduced by 16% in the screening group compared with the control 
group, although this was reduced to an 11% reduction when treatment complications 
were included (see Table 2).13 This result was not statistically significant, in contrast 
to estimates at shorter follow-up periods, including 10 years.14 Results at 14 years 
follow-up were of borderline significance.15 
Pooling the most recent data from the Nottingham and Funen-1 trials (excluding 
treatment complications) estimated that screening reduced the risk of death from CRC 
by 14% [RR = 0.86 (95% CI 0.79-0.93)]. Adding the results for biennial screening 
from the Minnesota RCT10 made no difference to the pooled rate ratio [RR = 0.85 
(95% CI 0.79-0.92)]. There was no evidence of heterogeneity between studies using 
Cochran’s Q test. 
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Table 1. Characteristics of trials of faecal occult blood screening with or without flexible 
sigmoidoscopy screening 
 
Variables Minnesota10,11 Nottingham12 Funen-113 Jiashan16 Funen-220 
Study population Minnesota, USA, 
volunteers aged 50-80 
years 
Nottingham, UK, 
aged 45-74 years 
Funen, 
Denmark, aged 
45-75 years 
Jiashan County, 
China, aged ≥ 30 
years 
Funen, 
Denmark, 
aged 50-75 
years 
Intervention Guaiac FOBT, 
predominantly 
rehydrated 
Guaiac FOBT, 
unrehydrated 
Guaiac FOBT, 
unrehydrated 
Immunochemical 
FOBT(reverse 
passive 
haemagglutination 
test) plus structured 
health questionnaire 
Once only 
Guaiac FOBT 
+ FS 
Control Usual care Usual care Usual care Not reported FOBT alone 
Study groups Annual screen 15,570 
Biennial screen 15,587 
Control 15, 394 
Biennial screen 
76,466 
Control 76,384 
Biennial screen 
30,967 
Control 30,966 
Once only screen 
94,423 
Control 97,838 
Once only 
Intervention 
group 5495 
Control 5483 
Screening rounds Annual group: 11 
Biennial group: 6 
≥3 9 1 1 
Participation rate First round: 
Annual group 90% 
Biennial group 89% 
Average compliance 
Annual 75% 
Biennial 75% 
First round: 
53% 
Overall (after re-
inviting non-
responders) 59% 
First round: 
67% 
Further rounds: 
91-97% 
One-off screen: 
66.4% 
FOBT +FS: 
40% 
FOBT alone: 
56% 
 
Follow-up 18 years Median 11.7 years 17 years 8 years 2-5 years 
Management of 
positive screen 
Colonoscopy Colonoscopy Review plus 
colonoscopy 
Flexible 
sigmoidoscopy 
Colonoscopy 
 
The report of the Jiashan trial provided data that allowed for calculations of the 
relative risks for CRC incidence and cumulative mortality following screening with 
an immunochemical FOBT.16 The only statistically significant result pertaining to 
incidence and mortality was a 32% reduction [RR = 0.68 (95% CI 0.54-0.87)] in 
mortality from rectal cancer in the screening group compared to the control group. 
Incidence of rectal cancer was not significantly reduced. In addition, for both colonic 
cancer and overall colorectal cancer, there was no significant reduction in mortality or 
incidence. This may reflect the fact that most screen positive participants underwent 
evaluation of only the distal part of the bowel, by flexible sigmoidoscopy. It was not 
clear whether an intention to treat analysis was used in this trial, nor whether cluster 
randomisation was taken into account. Overall results are presented in Table 2. 
Efficacy of flexible sigmoidoscopy screening—No completed RCT was identified 
which evaluated the impact of flexible sigmoidoscopy (FS) on colorectal cancer 
incidence and mortality. However, three large multi-centre trials are currently 
underway, with two exploring one-time screening17,18 and one exploring repeated 
screening.19 Incidence and mortality data will not be available until at least 2008 for 
the two one-off screening trials, and not until 2010–2012 for the repeated screening 
trial. 
Efficacy of flexible sigmoidoscopy screening and faecal occult blood testing 
combined—One RCT, the Funen-2 trial, reported limited CRC incidence and 
mortality data for 5495 persons registered for once-only FOBT and FS testing 
compared with 5483 persons receiving FOBT alone.20  
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At 24–62 months follow-up, 11 versus 14 persons died of CRC for combined versus 
FOBT-only groups (p value not reported), and the CRC incidence rate of those 
screened in the combined screening group was 3.6 compared to 5.9 per 1000 in the 
FOBT-only group (p=0.24). The predictive value of a positive test for CRC was 2.8% 
after FOBT followed by FS, and 5.4% after FOBT alone. Subjects and physicians 
were unaware of FOBT results before FS and the criteria for a positive test resulted in 
18.6% of the combined screening subjects having a full colonic examination 
compared to 2.3% after a positive FOBT test. See Table 2 for overall results. 
 
Table 2. Results of trials of faecal occult blood screening with or without flexible 
sigmoidoscopy screening 
 
Variables Minnesota10,11 Nottingham12,28 Funen-113 Jiashan16 Funen-220 
CRC mortality: 
Effectiveness 
RR (95%CI) 
Annual screening 
RR 0.67 (0.51–0.83) 
Biennial screening 
RR 0.79 (0.62–0.97) 
0.87 (0.78–0.97) CRC mortality 
(including treatment 
complications): 0.89 
(0.78-1.01) 
CRC mortality 
alone: 0.84 (0.73–
0.96) 
0.85 (0.71–1.03) 0.78 (0.36–1.73) 
NNS to avoid 
one CRC death 
(95% CI) 
Annual screening: 
268 (169 – 645) over 
18 years  
 
Biennial screening: 
499 (NNSH3740 - ∞ 
- NNSB234)1 over 
18 years  
826 (470 – 3390) 
over 11.7 years  
449 (250 – 2184) 
over 18 years  
27782 over 8 
years  
1813 (NNSH812–
∞–NNSB428)1 
over a range of 2–
5 years  
CRC incidence: 
Effectiveness 
RR (95%CI)  
Annual screening: 
RR 0.79 (0.62–0.97) 
Biennial screening: 
RR 0.83 (0.73–0.94) 
0.99 (0.92–1.07) 1.02 (0.93–1.12) 0.98 (0.86–1.13) 1.37 (0.88–2.15) 
Positive 
predictive value 
for CRC 
Annual screening: 
0.87%- 4.53% 
Biennial screening: 
1.12% (1 of 6 slides 
positive) 6.13% (6 of 
6 slides positive) 
 
First screen = 9.9% 
Later invitation to 
those who refused 
first screen = 
17.1% 
Rescreen = 11.9%–
13.3% 
 
First screen = 
17.2% 
Ninth screen = 
16.5%  
Rounds 2-8 range = 
5.2%-18.7% 
FOBT + 
questionnaire = 
0.66%  
 
 
First and once-
only screen  
 
FOBT+FS: 2.8% 
 
FOBT: 5.4% 
1) NNSH number needed to screen (harm), NNSB number needed to screen (benefit)  
2) Insufficient information for confidence interval calculation 
 
Discussion 
There was high-quality evidence that screening with the guaiac FOBT Haemoccult 
reduces mortality from CRC. However, the three trials examining this screening test 
had important differences in their design. FOBT rehydration was undertaken in most 
screening in the Minnesota trial, but not the Nottingham and Funen-1 trials.  
Rehydration increases the proportion of positive tests (which decreases the positive 
predictive value) and the number of diagnostic work-ups escalates. A higher rate of 
participants undergoing diagnostic work-up (with removal of adenomas) may explain 
why follow-up papers from the Minnesota RCT report a reduction in incidence of 
CRC, compared to both the Nottingham and Funen-1 trials, which found no difference 
  
NZMJ 20 July 2007, Vol 120 No 1258 Page 5 of 8 
URL: http://www.nzma.org.nz/journal/120-1258/2629/ © NZMA 
 
in incidence of CRC between screening and control groups.11 Nevertheless, test 
rehydration inflates screening costs, as well as increasing potential screening harms 
from the more invasive diagnostic tests.  
Currently, rehydration of guaiac-based FOBTs is not recommended by major 
organisations such as the World Health Organization21 and the American 
Gastroenterological Association,22 or by the manufacturer.23  
Another important difference was in the method of participant recruitment. Since both 
the Nottingham and Funen-1 studies used population-based sampling, their results are 
the most applicable to organised population screening programmes (the Minnesota 
study used a volunteer population). Of interest in this respect is that participation rates 
for at least one round in these population-based RCTs was between 59–67%. This was 
similar to the participation rate (66.4%) of the Jiashan trial, which also invited 
members of the general public. The Minnesota RCT participation rate was higher 
(89–90% for the first round).5. 
Despite these differences, the three trials estimated reduced rates of CRC mortality in 
the screening groups, although CRC mortality was not significantly reduced after 
longer-term follow-up in the Funen-1 trial. Evidence from ongoing follow-up of the 
two trials in which screening has stopped (Minnesota and Nottingham) suggests that 
this mortality reduction has been sustained. However, CRC mortality was not 
significantly reduced after longer term follow up in the Funen-1 trial for the 
population to whom screening has continued to be offered; Kronborg et al suggest 
that this lessening of risk reduction is likely to be due to smaller numbers of subjects 
being screened as the number of screening rounds increases.13 
Pooled estimates of the two population based trials examining guaiac FOBT 
(Nottingham and Funen-1) or the three guaiac based RCTs (Minnesota, Nottingham, 
and Funen-1) suggests that screening resulted in significantly reduced colorectal 
cancer mortality. These results are similar to those found by Towler et al24 who 
estimated a 16% reduction in mortality from colorectal cancer in a meta-analysis of 
earlier results. The Towler meta-analysis included the Minnesota, Nottingham, and 
Funen-1 trials (though with shorter-term follow-up) plus data obtained by personal 
communication from the Gothenburg RCT.25 
The Jiashan trial was the only eligible study that evaluated an immunochemical test 
and was therefore included for comparative purposes. Nevertheless, differences in age 
and healthcare environment somewhat limit the clinical relevance of this study. It was 
difficult to evaluate what influence the young average age of the study population in 
this RCT may have had on the efficacy of screening to reduce CRC mortality. 
However, given the overall youth of the study population (and therefore the probable 
lower incidence of CRC in such a group) the impact of screening would likely have 
been reduced in this trial.  
The investigators justified their choice of start age by explaining that CRC occurs 
approximately 10 years earlier in Chinese than in Westerners; this ethnic difference 
also limits how applicable the results of the Jiashan RCT are to the New Zealand 
population.16  
Since the management of screen positive participants differs from that of the three 
studies that examined guaiac FOBTs, the results from this study are not directly 
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comparable. Although the evidence from this study suggests that a reduction in rectal 
cancer may be achievable with the use of an immunochemical test, for the reasons 
outlined above and in the results section this evidence is less robust than that provided 
by the other three RCTs included in this section. 
Although population-based surveillance using flexible sigmoidoscopy has been 
investigated,26 no large RCT of this method has been completed that provided 
incidence and mortality data. Three large ongoing trials are investigating flexible 
sigmoidoscopy as either one-off or repeated screening for average-risk men and 
women aged from their mid-50s.  
Preliminary results are promising in terms of feasibility and acceptability. However, 
incidence and mortality data will not be available before 2008 for the two trials 
investigating one-off screening (personal correspondence, Professor Wendy Atkin, 
principal investigator, Flexible Sigmoidoscopy Screening Trial, 15 February 2005; 
personal correspondence, Dr Carlo Senore, SCORE Trial, 16 March, 2005), and until 
2010–2012 for the trial of repeated screening (personal correspondence, Dr Schoen, 
investigator, The Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, 23 
February 2005).  
The Funen-2 trial with FOBT followed by FS had a short follow-up period and non-
repeat screening and was not designed as a mortality study. The trial evidence does 
not support a FOBT and FS combined screening strategy in asymptomatic middle-
aged populations over screening involving FOBT alone. These results could reflect 
poor compliance in the combined screening group and, in those attending, few 
additional positive results from FOBT that were not already reported by FS.  
The Norwegian Colorectal Cancer Prevention (NORCCAP) trial2 comparing FS 
screening with no intervention considered FOBT and FS combined compared with FS 
alone within the trial intervention arm. Data on CRC incidence and mortality is 
expected to become available in late 2007 (personal correspondence, Professor G. 
Hoff, Investigator, NORCCAP Screening Trial, 8 March 2005).  
Conclusion 
This review has examined the efficacy of screening for CRC using FOBT testing with 
or without FS. The estimated reduction in CRC mortality resulting from screening 
with guaiac-based FOBT in large randomised controlled trials with long follow-up 
provides support for the use of this test. No such evidence exists for screening with FS 
either alone, or in combination with FOBT, but this should be re-evaluated once data 
become available from four large ongoing trials.  
To replicate the mortality reductions found in the FOBT trials, participation in a 
screening programme would need to be equivalent or higher. Screening acceptability 
may represent one of the biggest challenges for FOBT screening. This paper has not 
examined other issues of relevance to the use of screening for colorectal cancer 
screening, including risk of harm from screening, resources available for the 
management of screen positive individuals and the economic implications resulting 
from screening. These are discussed further in the full report of the systematic 
review.5 Such factors are important considerations that may influence the decision to 
introduce a colorectal screening programme based on FOBT testing. 
Competing interests: None. 
  
NZMJ 20 July 2007, Vol 120 No 1258 Page 7 of 8 
URL: http://www.nzma.org.nz/journal/120-1258/2629/ © NZMA 
 
Disclaimer: Views expressed in this article do not necessarily represent the views of the Ministry of 
Health. 
Author information: Jane Kerr, Research Fellow; Peter Day, Research Fellow; 
Marita Broadstock, Research Fellow; Robert Weir, Director and Senior Research 
Fellow; Susan Bidwell, Information Specialist Manager 
New Zealand Health Technology Assessment (NZHTA), Department of Public Health 
and General Practice, University of Otago, Christchurch 
Acknowledgements: The Ministry of Health funded this research and allows the 
NZMJ to publish this article. We acknowledge contributions to the NZHTA report by 
Sarah Hogan, Susan Parry, Ann Richardson, Simon Baker, Bronwyn Petrie, and Terri 
Green.  
Correspondence: Robert Weir, New Zealand Health Technology Assessment, 
Department of Public Health and General Practice, University of Otago, PO Box 
4345, Christchurch. Fax: (03) 364 3697; email: robert.weir@chmeds.ac.nz  
References: 
1. Minister of Health. The New Zealand cancer control strategy. Wellington: Ministry of Health 
and the New Zealand Cancer Control Trust; 2003. 
2. New Zealand Health Information Service. Cancer: new registrations and deaths 2000. 
Wellington: Ministry of Health; 2004. 
3. Working Party on Screening for Colorectal Cancer. Population screening for colorectal 
cancer. Wellington: National Health Committee; 1998. 
4. Anonymous. Recommendations on population screening for colorectal cancer in New 
Zealand. Members of the National Health Committee Working Party on Population Screening 
for Colorectal Cancer. N Z Med J. 1999;112:4–6. 
5. Kerr J, Broadstock M, Day P, Hogan S. Effectiveness and cost-effectiveness of population 
screening for colorectal cancer: a systematic review of the literature. NZHTA Report. 
2005;8(1):1–186. 
6. Jackson R. The GATE approach: teaching and learning evidence-based practice with pictures. 
2005 [cited 2005 Dec 9] http://www.health.auckland.ac.nz/population-health/epidemiology-
biostats/epiq/updatedGATESicily.pdf  
7. Law MR. The number needed to screen--an adaptation of the number needed to treat. J Med 
Screen. 2001;8:114–5. 
8. Altman DG. Confidence intervals for the number needed to treat. BMJ. 1998;317:1309–12. 
9. StataCorp. Stata statistical software: release 7.0. College Station, TX: Stata Corporation; 
2001. 
10. Mandel JS, Church TR, Ederer F, Bond JH. Colorectal cancer mortality: effectiveness of 
biennial screening for fecal occult blood. J Natl Cancer Inst. 1999;91:434–7. 
11. Mandel JS, Church TR, Bond JH, et al. The effect of fecal occult-blood screening on the 
incidence of colorectal cancer. N Eng J Med. 2000;343:1603–7. 
12. Scholefield JH, Moss SM. Faecal occult blood screening for colorectal cancer. J Med Screen 
2002;9:54–5. 
13. Kronborg O, Jorgensen OD, Fenger C, Rasmussen M. Randomized study of biennial 
screening with a faecal occult blood test: Results after nine screening rounds. Scand J 
Gastroenterol 2004;39:846–51. 
14. Kronborg O, Fenger C, Olsen J, et al. Randomised study of screening for colorectal cancer 
with faecal-occult-blood test. Lancet. 1996;348:1467–71. 
  
NZMJ 20 July 2007, Vol 120 No 1258 Page 8 of 8 
URL: http://www.nzma.org.nz/journal/120-1258/2629/ © NZMA 
 
15. Jorgensen OD, Kronborg O, Fenger C. A randomised study of screening for colorectal cancer 
using faecal occult blood testing: results after 13 years and seven biennial screening rounds. 
Gut. 2002;50:29–32. 
16. Zheng S, Chen K, Liu X, et al. Cluster randomization trial of sequence mass screening for 
colorectal cancer. Dis Colon Rectum. 2003;46:51–8. 
17. U. K. Flexible Sigmoidoscopy Screening Trial Investigators. Single flexible sigmoidoscopy 
screening to prevent colorectal cancer: baseline findings of a UK multicentre randomised trial. 
Lancet. 2002;359:1291–300. 
18. Segnan N, Senore C, Andreoni B, et al. Baseline findings of the Italian multicenter 
randomized controlled trial of "once-only sigmoidoscopy"—SCORE. J Natl Cancer Inst. 
2002;94:1763–72. 
19. Schoen RE, Pinsky PF, Weissfeld JL, et al. Results of repeat sigmoidoscopy 3 years after a 
negative examination. JAMA. 2003;290:41–8. 
20. Rasmussen M, Kronborg O, Fenger C, Jorgensen OD. Possible advantages and drawbacks of 
adding flexible sigmoidoscopy to hemoccult-II in screening for colorectal cancer. A 
randomized study. Scand J Gastroenterol. 1999;34:73–8. 
21. Young GP, St John DJ, Winawer SJ, et al. Choice of fecal occult blood tests for colorectal 
cancer screening: recommendations based on performance characteristics in population 
studies: a WHO (World Health Organization) and OMED (World Organization for Digestive 
Endoscopy) report. Am J Gastroenterol. 2002;97:2499–507. 
22. Winawer SJ. Colorectal cancer screening comes of age. N Eng J Med. 1993;328:1416–7. 
23. Allison JE. Screening for colorectal cancer 2003: Is there still a role for the FOBT? Tech 
Gastrointest Endosc. 2003;5:127–33. 
24. Towler B, Irwig L, Glasziou P, et al. A systematic review of the effects of screening for 
colorectal cancer using the faecal occult blood test, hemoccult. BMJ. 1998;317:559–65. 
25. Kewenter J, Brevinge H, Engaras B, et al. Results of screening, rescreening, and follow-up in 
a prospective randomized study for detection of colorectal cancer by fecal occult blood 
testing. Results for 68,308 subjects. Scand J Gastroenterol. 1994;29:468–73. 
26. Thiis-Evensen E, Hoff GS, Sauar J, et al. The effect of attending a flexible sigmoidoscopic 
screening program on the prevalence of colorectal adenomas at 13-year follow-up. Am J 
Gastroenterol. 2001;96:1901–7. 
27. Gondal G, Grotmol T, Hofstad B, et al. The Norwegian Colorectal Cancer Prevention 
(NORCCAP) screening study: baseline findings and implementations for clinical work-up in 
age groups 50-64 years. Scand J Gastroenterol 2003;38:635–42. 
28. Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-
occult-blood screening for colorectal cancer. Lancet 1996;348:1472–7. 
 
 
